Navigation Links
ITN type 1 diabetes study identifies subset of patients with strong response to therapy
Date:8/15/2013

p).

Further analysis revealed that within the treatment arm two groups of patients could be distinguished based on their C-peptide levels: one group, considered "responders" (22/49), showed very little C-peptide decline over the course of the study (only a 6 percent reduction from baseline), while the "non-responders" (27/49) exhibited a similar rate of C-peptide decline as the control group (less than 40-percent reduction from baseline).

Investigators measured various biomarkers and cell types that might distinguish between these two groups. They found that, at trial entry, "responders" had lower hemoglobin A1c levels (a marker of glucose concentration in the blood) and used less insulin at baseline, compared to "non-responders". Differences in specific T-cell subsets also distinguished between the two groups at baseline, suggesting that immune status might contribute to drug responsiveness. However, further studies will be required to confirm these results.

"This overall approach to identifying characteristics of individuals most likely to respond to therapies shows great promise because the responders in this study experienced a robust and prolonged drug effect," said Dr. Herold. "This type of response has not been seen in other studies of immune therapies."

Type 1 diabetes is a disease marked by immune destruction of insulin-producing beta cells in the pancreas. New-onset patients usually have 20 to 40 percent of their normal beta cell mass remaining, which is still capable of producing insulin. Preserving this remaining mass, even temporarily, could improve long-term clinical outcomes.

Immune modulators, like teplizumab, represent a promising means of inducing tolerance; however, no drug has been shown to prevent or reverse disease, and only a few have temporarily delayed disease progression. The ability to identify a subgroup of patients who may be more responsive to therapy could greatly enhance the clinical use
'/>"/>

Contact: Philip Bernstein, Ph.D.
ITNCommunications@immunetolerance.org
240-235-6132
Immune Tolerance Network
Source:Eurekalert

Page: 1 2 3

Related biology news :

1. Diabetes Research Institute develops oxygen-generating biomaterial
2. New study shines light on barriers to diabetes care in NYC Bangladeshi community
3. Commonly used diabetes drug may help to prevent primary liver cancer
4. Approach to diabetes self-management too narrow, study suggests
5. Gut microbiota transplantation may prevent development of diabetes and fatty liver disease
6. From feast to famine: A metabolic switch that may help diabetes treatment
7. Increased fructose consumption may deplete cellular energy in patients with obesity and diabetes
8. Jack Spratt diabetes gene identified
9. Diabetes drug makes brain cells grow
10. Obesity plus low vitamin D may add up to a greater risk of diabetes
11. Joslin researchers gain new understanding of diabetes and kidney disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... WA Nearly 600 scientists from 25 countries ... Genetics Meeting organized by the Genetics Society of ... Washington in Seattle. The conference will feature close ... research results on topics including gene expression and ... emerging technologies, evolution, aging, and a variety of ...
(Date:7/25/2014)... consume the healthcare community and remain priority ... To address the worldwide crisis of obesity ... global leaders in diabetes, epidemiology and public ... and development of diverse intervention programs in ... This book on "Global Health Perspectives in ...
(Date:7/25/2014)... pleiotropic factor characterized by the existence of numerous ... confer to the protein deeply different characteristics. NRG1 ... occurring during development and the different phases occurring ... axon regrowth, remyelination and target reinnervation, Researchers at ... the soluble NRG1 upregulation observed in Schwann cells ...
Breaking Biology News(10 mins):Yeast meeting to showcase latest breakthroughs in genetics and molecular biology 2What constitutes an effective response to the global 'diabesity' tsunami? 2
... KINGSTON, R.I. March 1, 2010 In one of ... of natural and social scientists from the University of Rhode ... among the most important factors driving the success of marine ... marine reserve is just about coral, fish and other aquatic ...
... researchers have found a way to stitch graphene and ... offers new paths of exploration for materials scientists. ... in microelectronics that scale well below the limitations of ... the lab of Pulickel Ajayan, Rice,s Benjamin M. and ...
... Moines, Iowa March 1, 2010 You may have ... bonobos living at Great Ape Trust, than you thought. And ... scientists more about the effect of culture on neurological disorders ... universal language, an alternative to spoken words to convey a ...
Cached Biology News:Scientists find community involvement, not only enforcement, drives success of marine reserves 2Rice researchers make graphene hybrid 2Rice researchers make graphene hybrid 3If bonobo Kanzi can point as humans do, what other similarities can rearing reveal? 2If bonobo Kanzi can point as humans do, what other similarities can rearing reveal? 3
(Date:7/25/2014)... WABC Radio show out of New York City, ... will be hosting California-based Vet-Stem, Inc.’s Founder and CEO, Robert ... pets. Dr. Harman first visited the show in November ... pets suffering from osteoarthritis and other degenerative diseases, as well ... , Young has invited Dr. Harman back to dial down ...
(Date:7/25/2014)... 2014 Lawrence Livermore scientists Charles Westbrook ... list of " The World's Most Influential Scientific Minds ... 3,000 researchers who were identified by analyzing citation data ... published the highest-impact work (2002-2012 and 2012-2013). The two ... combustion modeling . , "This recognition is a great ...
(Date:7/25/2014)... BENSALEM, Pa. , July 25, 2014 /PRNewswire-iReach/ ... services and consulting for global corporations operating in ... will host its first annual Global User Group ... in historic Philadelphia, Pennsylvania ... Photo - http://photos.prnewswire.com/prnh/20140724/130263 ...
(Date:7/25/2014)... 2014 Sinovac Biotech Ltd. (Nasdaq: SVA ... China , today announced that it will release its ... 2014, after market close on Thursday, August 14, 2014 EDT. ... market opening on Friday, August 15, 2014, at 8:00 a.m. ... Time) to review the Company,s financial results and provide an ...
Breaking Biology Technology:Robert J. Harman, DVM, Founder and CEO of Vet-Stem, Inc. to Join New York Radio Host Lorry Young in Upcoming Episode of A “Paws” For Your Pet 2Robert J. Harman, DVM, Founder and CEO of Vet-Stem, Inc. to Join New York Radio Host Lorry Young in Upcoming Episode of A “Paws” For Your Pet 3Scientists Burst onto Influential List for Combustion Research 2Scientists Burst onto Influential List for Combustion Research 3Scientists Burst onto Influential List for Combustion Research 4Xybion Announces It Will Host International User Conference in Philadelphia 2Xybion Announces It Will Host International User Conference in Philadelphia 3Sinovac to Host Conference Call to Report Second Quarter 2014 Unaudited Financial Results 2
... PARIS, September 30 , ... Needed to Achieve Similar, Well,Tolerated Glycemic Control Versus Lantus(R) , ... SNY ) announced today results of a,head-to-head study providing further ... glargine [rDNA] injection) compared,to twice-daily insulin detemir. The study was ...
... Biotherapeutics, Inc. (OTC Bulletin Board: OXBO) today announced ... chairman and CEO, Chris Stern, is now available ... presentation can be found under the "Presentations" heading ... at www.oxybiomed.com. It can also be accessed via ...
... lecturer from the Nanyang Technological University (NTU) received the ... nanostructures and graphene, which are used to develop nanodevices ... won in the Physical, Information and Engineering Services category ... with the Division of Physics and Applied Physics at ...
Cached Biology Technology:Superior Efficacy-dose Ratio for Lantus(R) Over detemir 2Superior Efficacy-dose Ratio for Lantus(R) Over detemir 3Superior Efficacy-dose Ratio for Lantus(R) Over detemir 4Superior Efficacy-dose Ratio for Lantus(R) Over detemir 5NTU assistant professor wins Young Scientist Award 2NTU assistant professor wins Young Scientist Award 3
...
I-Ab MHC Class II...
BD Falcon Center-well 60 mm In Vitro Fertilization (IVF) Dish, nonembryotoxic, noncytotoxic, tissue-culture treated polystyrene. (20/sp, 500/ca) Packaging: 20 / sleeve, 500 / case ...
... 60 mm Culture Dishes BD BioCoat Collagen ... with a uniform application of rat tail collagen ... I ,Surface : ECM/attachment factors ... nominal : 60 mm x 15 mm ...
Biology Products: